Syros Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	11.9yrs

Recent management updates

Recent updates

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Jul 02

CEO

Syros Pharmaceuticals has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	11.9yrs	no data	no data
Mark Murcko	Member of Scientific Advisory Board	11.9yrs	no data	no data
Robert Weinberg	Member of Scientific Advisory Board	11.9yrs	no data	no data
Roger Tung	Member of Scientific Advisory Board	no data	no data	no data
Gerald Quirk	Director	no data	US$1.46m	0% $ 0
Gerard Evan	Member of Scientific Advisory Board	11.9yrs	no data	no data
Scott Biller	Member of Scientific Advisory Board	11.9yrs	no data	no data
Bradley Bernstein	Member of Scientific Advisory Board	no data	no data	no data
Stefan Knapp	Member of Scientific Advisory Board	11.9yrs	no data	no data
Aviv Regev	Member of Scientific Advisory Board	11.9yrs	no data	no data
Chris Vakoc	Member of Scientific Advisory Board	11.9yrs	no data	no data

11.9yrs

Average Tenure

63yo

Average Age

Experienced Board: SYRS's board of directors are seasoned and experienced ( 11.9 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/24 18:53
End of Day Share Price	2025/03/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Syros Pharmaceuticals, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mark Breidenbach	Oppenheimer & Co. Inc.
Zegbeh Jallah	Roth Capital Partners
Philip Nadeau	TD Cowen

Syros Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025

Chief Financial Officer recently bought US$161k worth of stock

Scientific Founder notifies of intention to sell stock

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Director exercised options and sold US$72k worth of stock

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Recent updates

Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index

Syros Pharmaceuticals Announces Voluntary Delisting from Nasdaq and SEC Deregistration

Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025

Syros Pharmaceuticals, Inc. Receives Deficiency Letters From Nasdaq

New major risk - Market cap size

New major risk - Revenue and earnings growth

Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Chief Financial Officer recently bought US$161k worth of stock

Price target decreased by 56% to US$8.75

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

New major risk - Financial position

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Scientific Founder notifies of intention to sell stock

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Director exercised options and sold US$72k worth of stock

Consensus revenue estimates decrease by 59%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Forecast to breakeven in 2026

Price target decreased by 12% to US$20.00

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

New major risk - Share price stability

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Price target decreased by 16% to US$21.25

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Price target decreased by 16% to US$21.25

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 10% to US$26.50

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Price target decreased to US$25.40

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Consensus revenue estimates fall by 11%

Insufficient new directors

Consensus forecasts updated

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought US$106k worth of stock

Consensus forecasts updated

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

Consensus forecasts updated

Consensus estimates of losses per share improve by 11%